Pediatrix earnings top estimates on strong reimbursement trends

Pediatrix Medical Group (NYSE:MD) reported first-quarter earnings that beat Wall Street estimates on both the top and bottom lines, as favorable reimbursement shifts helped the physician services leader overcome a softer volume environment.

The Fort Lauderdale-based company reported net revenue of $476.2 million for the quarter ended March 31, 2026, a 3.9% increase year-over-year.

While overall patient volumes saw modest pressure—with NICU days down 0.8% and office-based services down 3.3%—same-unit revenue from net reimbursement-related factors surged 4.4%, reflecting the company’s successful efforts to align pricing with rising clinical costs.

Profitability metrics showed significant year-over-year improvement.

Adjusted EBITDA reached $58.2 million, compared to $49.2 million in the prior-year period.

On a per-share basis, Pediatrix reported GAAP earnings of $0.36 and adjusted EPS of $0.44, comfortably surpassing the analyst consensus of $0.38.

Practice salaries and benefits expense rose to $345.7 million, up from $337 million, as the company addressed same-unit clinical salary increases.

However, general and administrative expenses remained relatively stable at $60.3 million, highlighting management's focus on operational efficiency following a period of organizational realignment.

During the quarter, Pediatrix remained active in capital deployment, using $21.5 million for share repurchases and $7 million to fund strategic acquisitions, including an expansion of maternal-fetal medicine services in Tennessee.

The company ended the period with total debt of $591 million and a healthy liquidity position, with no outstanding borrowings on its $450 million revolving credit line.

Based on the strong start to the year, Pediatrix reaffirmed its full-year 2026 adjusted EBITDA guidance range of $280 million to $300 million.